Citeline, Biomedtracker: see the drug development process th...
Catch up on any missed COVID-19 24 hour webinar sessions
Jared Wolff, Zach McLellan, Kevin Shannon and Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast.
Topics covered in this episode include:
- Kite Therapeutics (KITE) axicabtagene ciloleucel development update - 0:34
- Review of recent data from oral statin add-on therapies bempedoic acid (ESPR) and gemcabene (GEMP)- 4:47
- Fibrogren (FGEN) and Galapagos (GLPG) data readouts in idiopathic pulmonary fibrosis - 12:01
- PARP second quarter earnings review (AZN, TSRO, CLVS, PFE)- 16:50
Click here to learn more about Datamonitor Healthcare and our offerings
Datamonitor Healthcare: data analysis and insight, Pink Shee...
By Tara Hansen
The FDA Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals has already led to withdrawals of four PD-1/PD-L1 inhibitor indications, with the Oncologic Drugs Advisory Committee set to review another six in late April. Over the next two years, an additional five indications may be up for review.
Datamonitor Healthcare: data analysis and insight
Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: